Abstract
Questioning Patient Subgroups for Benefit Assessment: Challenging the German Gemeinsamer Bundesausschuss Approach Jorg Ruof, MD, MPH, MBA*, Charalabos-Markos Dintsios, PhD, MPH, Friedrich Wilhelm Schwartz, MD Roche Pharma AG, Grenzach-Wyhlen, Germany; Hannover Medical School, Hannover, Germany; German Association of Researchbased Pharmaceutical Companies (vfa), Berlin, Germany; Department of Public Health, Heinrich Heine University, Dusseldorf, Germany
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
